On this page ▾
Key takeaways
- An independent committee found no safety concerns in Sensorion’s gene therapy trial for deafness caused by a faulty OTOF gene.
- Two of three children in the higher-dose group showed early hearing improvement at three months, sustained at six months.
- In June 2026 Sensorion stopped developing SENS-501; in April 2026 the US approved a different OTOF gene therapy.
- Hearing aids and cochlear implants remain the main options for many children with this type of deafness.
- These are early results from very few children, so lasting benefit is not yet known.
In December 2025, Sensorion said an independent committee had found no safety concerns so far in its Phase 1/2 trial of SENS-501, an experimental gene therapy for babies and toddlers born deaf because of a faulty OTOF gene1. Update, June 2026: Sensorion has since stopped developing SENS-501 and ended recruitment to the trial, and says it will keep following up the children already treated3. Separately, in April 2026 the US Food and Drug Administration approved a different gene therapy for OTOF-related hearing loss, Regeneron’s Otarmeni4.
If you are the parent of a child with hearing loss, your child’s audiology team can explain which options apply to your family.
Sensorion is a French clinical-stage biotechnology company focused on treatments for hearing loss and balance disorders. The independent committee reviewed the first stages of the Audiogene Phase 1/2 trial and allowed the study to continue at the time1.
What was the trial testing?
The Audiogene trial was testing SENS-501, an experimental gene therapy for children born with deafness caused by a faulty OTOF gene. This gene is essential for passing sound signals from the inner ear hair cells to the auditory nerve.
Children were 6 to 31 months old when treated, and each child was treated in one ear.
What did the safety review find?
An independent data monitoring committee examined early data from the first two small groups of children in the study. The second group had three children. Sensorion said the committee found that the procedure was well tolerated and that no serious side effects were reported. Based on that review, the committee supported continuing the trial as planned.
Did hearing improve?
Sensorion has also shared early indications that the gene therapy may be having an effect. In the second group of three children, two showed early improvement on pure-tone hearing tests three months after treatment, and Sensorion later reported that the improvement was sustained at six months2. At their best frequency, their thresholds were about 60 and 70 dB HL, which is still a significant hearing loss.
The company stressed that these are early signals from very few children. More time and data are needed to understand whether the changes are lasting and meaningful in everyday listening.
Why does this matter?
For families affected by congenital deafness linked to the OTOF gene, current options are limited. Management options such as hearing aids or cochlear implants help many children, but they do not address the underlying cause.
SENS-501 aimed to treat the cause by giving the inner ear a working copy of the gene, so that sound signals can reach the auditory nerve. Whether it can do that safely and lastingly was still being tested. See also our articles on gene therapy for congenital deafness and newborn hearing screening.
Why caution remains
“Any research involving very young children quite rightly moves slowly,” said Jessica Tovey, a Clinical Audiologist at Hearology. “Seeing reassuring safety data is an important first step, but it will take time to know whether this kind of treatment can make a real difference for families.”

Frequently asked questions
Can gene therapy cure deafness?
What is OTOF hearing loss?
What helps children born deaf today?
How is a baby’s hearing checked?
References:
- [1] Sensorion, "Sensorion reports independent Data Monitoring Committee raises no safety concerns and agrees to continue SENS-501's Audiogene Phase 1/2 trial," Dec. 8, 2025. Accessed: Nov. 16, 2026. [Online]. Available:
- [2] Sensorion, "Sensorion reports six month update from the Audiogene Phase 1/2 trial of SENS-501 and advances GJB2 GT SENS-601 toward first-in-human," Mar. 23, 2026, republished by Sofinnova Partners. Accessed: Nov. 16, 2026. [Online]. Available:
- [3] Sensorion, "Sensorion achieves key regulatory milestones for SENS-601 in GJB2-related hearing loss," Jun. 10, 2026, republished by Sofinnova Partners. Accessed: Nov. 16, 2026. [Online]. Available:
- [4] U.S. Food and Drug Administration, "OTARMENI," Vaccines, Blood and Biologics. Accessed: Nov. 16, 2026. [Online]. Available:
